|1.||Zhou, Jin: 25 articles (09/2015 - 11/2003)|
|2.||Kwong, Yok-Lam: 20 articles (03/2015 - 07/2003)|
|3.||Lo-Coco, Francesco: 16 articles (12/2015 - 06/2006)|
|4.||Jin, Jie: 16 articles (11/2015 - 06/2004)|
|5.||Chen, Zhu: 16 articles (06/2015 - 02/2002)|
|6.||Alimoghaddam, Kamran: 16 articles (01/2015 - 10/2005)|
|7.||Waxman, Samuel: 16 articles (12/2012 - 01/2002)|
|8.||Ghavamzadeh, Ardeshir: 15 articles (01/2015 - 10/2005)|
|9.||Tallman, Martin S: 15 articles (07/2014 - 01/2002)|
|10.||Kantarjian, Hagop: 14 articles (05/2015 - 05/2003)|
|1.||Acute Promyelocytic Leukemia
01/01/2011 - "Arsenic trioxide (ATO), a natural product that has improved the prognosis of acute promyelocytic leukemia (APL) from highly fatal to highly curable, has also been proven to be effective in treating BL cell lines through multiple pathways in our study. "
11/20/2014 - "Arsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). "
01/01/2013 - "Arsenic trioxide (As2O3) is a highly effective agent for treatment of acute promyelocytic leukemia (APL). "
08/11/2011 - "Arsenic trioxide (As₂O₃) is a highly effective treatment for patients with refractory/relapsed acute promyelocytic leukemia (APL), but resistance to As₂O₃ has recently been seen. "
05/01/2011 - "Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). "
11/28/2011 - "Arsenic trioxide (As2O3) has considerable efficacy in treating solid tumors with induction of apoptosis. "
07/08/2011 - "Knowledge of the mechanism by which arsenic trioxide exerts the anti-tumor effects may help in designing a more effective regimen for therapy. "
08/18/2008 - "Arsenic trioxide (As2O3) has considerable efficacy in treating solid tumors with induction of apoptosis with largely unknown mechanisms. "
06/01/2015 - "The therapeutic efficacy of arsenic trioxide (ATO) for treatments of solid tumors is restricted by its drug resistance and chemotoxicity. "
03/01/2012 - "Arsenic trioxide (As2O3) has shown therapeutic efficacy in the treatment of haematological and solid cancer and has been demonstrated to effectively induce apoptosis of HPV-infected cervical cancer cells in vitro. "
08/01/2014 - "Arsenic trioxide (As2O3) has remarkable therapeutic efficacy against leukemia. "
04/01/2011 - "Although treatment heterogeneity and suboptimal post-remission therapy must be taken into account, overall results and development of secondary leukemia in one patient suggest that effective and less toxic agents like arsenic trioxide warrants further investigation in this context."
07/01/2014 - "We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. "
01/01/2013 - "These studies raise the potential of future clinical-translational efforts employing combinations of arsenic trioxide with autophagy-modulating agents to promote elimination of early leukemic progenitors and, possibly, leukemia-initiating stem cells."
12/01/2012 - "This study characterized the role of endoplasmic reticulum stress (ERS)-related pathways in arsenic trioxide-induced apoptosis in multidrug-resistant leukemia K562/ADM cells. "
01/01/2013 - "Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). "
03/01/2004 - "Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice."
01/01/2006 - "Single-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). "
08/01/2009 - "The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review."
01/01/2011 - "Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study."
|5.||Hematologic Neoplasms (Hematological Malignancy)
03/01/2006 - "Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. "
01/01/2005 - "Arsenic trioxide (ATO), which acts through pro-apoptotic, antiproliferative, and anti-angiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. "
01/25/2015 - "Arsenic trioxide (ATO) is successfully used to treat hematological malignancies. "
04/01/2014 - "Efforts to enhance the antileukemic properties of arsenic trioxide are clinically relevant and may lead to the development of new therapeutic approaches for the management of certain hematological malignancies. "
07/01/2010 - "Combination therapy with arsenic trioxide for hematological malignancies."
|1.||Aligeron (AS 2)
|2.||Tretinoin (Retinoic Acid)
|4.||Ascorbic Acid (Vitamin C)
|5.||retinoic acid receptor alpha
|6.||promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
|9.||Arsenicals (Arsenic Compounds)
|1.||Drug Therapy (Chemotherapy)